Global GMP Cell Therapy Consumables Market Size is valued at USD 22.72 Bn in 2024 and is predicted to reach USD 312.91 Bn by the year 2034 at a 30.1% CAGR during the forecast period for 2025 to 2034.
GMP Cell Therapy Consumables Market Size, Share & Trends Analysis Report By Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy, Process, End User, Region, And Segment Forecasts, 2025 to 2034
Good Manufacturing Practices (GMP) ensure that products are manufactured and maintained under good quality standards. Cell therapy development processes are complex and require good pharmaceutical systems and quality control (QC).
The market growth is attributed to rising drug discovery, the high prevalence of cancer, cell therapy innovations, and the surging use of cell therapy & GMP cell therapy consumables. However, stringent regulatory policies may hamper the market growth. The increasing collaborations & partnership activities within companies operating in the GMP cell therapy consumables market for developing new products and cell therapy treatments also support the market growth. For instance, in March 2022, FUJIFILM Irvine Scientific, Inc. acquired Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Shenandoah Biotechnology recently launched their CTG Grade line of cytokines & growth factors manufactured according to cGMP guidelines in the company's new state-of-the-art, ISO 9001:2015 certified facility.
Moreover, the last five years have been a rebirth for cell therapy and gene therapy (CGT) innovation, and the COVID-19 pandemic has accelerated these developments.
The GMP Cell Therapy Consumables Market is segmented into Product, cell therapy, Process, and end user. By Product, the market is categorized into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins, and others. The cell therapy segment comprises NK cell therapy, stem cell therapy, T-cell therapy, and others. By Process, the market is divided into cell collection and characterization/sorting and separation, cryopreservationcell culture and expansion/preparation, cell processing and formulation, cell distribution/handling, cell isolation and activation, process monitoring and control/readministration/quality assurance, and others. The end user segment consists of clinical, commercial, and research.
The kits segment held the largest GMP cell therapy consumables market share in 2022. However, the growth factors/cytokines and interleukins segment is predicted to capture the highest CAGR over the forecast period.
In 2022, the T-cell therapy segment held the largest share of the GMP cell therapy consumables market. Various clinical trials on Chimeric antigen receptor (CAR) T-cell therapy are being conducted for cancer treatment. The therapy improves the immune system's power, protecting against infections by destroying harmful viruses & bacteria. Such increasing clinical trials of CAR T-cell therapy are surging the demand for GMP cell therapy consumables.
The cell collection, characterization/sorting, and separation segment are expected to drive the market during the forecast period. Moreover, the cryopreservation segment is anticipated to grow fastest in the coming years. Several companies in this market are building the GMP-compliant cell sorter to reduce contamination.
In 2022, the clinical segment led the GMP cell therapy consumables market. Increasing clinical trials due to the high prevalence of chronic diseases, rising clinical studies and research efforts for developing new cell therapies are expected to enhance the market growth over the projected period.
Factors such as the increasing demand for cell therapies, the surging use of GMP cell therapy consumables, and rising research efforts in drug discoveries are responsible for the blooming of the GMP Cell Therapy Consumables Market in North America. At the same time, the Asia Pacific regional market is predicted to register the swiftest growth in the upcoming years. Growing cancer cases, chronic diseases, autoimmune disorders, and infectious diseases, increasing adoption of GMP cell therapy consumable products in India, and the development of cell therapy products are among the factors supporting the growth of the GMP Cell Therapy Consumables Market in this region.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 22.72 Bn |
| Revenue Forecast In 2034 | USD 312.91 Bn |
| Growth Rate CAGR | CAGR of 30.1% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Cell Therapy, By Process, By End User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Sartorius AG, Thermo Fisher Scientific Inc., Miltenyi Biotec BV & Co KG, Bio-Techne Corp, Corning Inc., FUJIFILM Irvine Scientific Inc., Lonza Group AG, BPS Bioscience Inc., Merck KGaA, Global Life Sciences Solutions USA LLC., and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.